First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults

Documenti analoghi

• A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males
  di: Emmanuel Biver, et al.
  Pubblicazione: (2026)
• Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
  di: Martin Coenen, et al.
  Pubblicazione: (2025)
• In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
  di: Linda Wanika, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial
  di: Andrew Leber, et al.
  Pubblicazione: (2025)
• Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline‐Induced Cardiotoxicity Using an Integrated PK / PD Model
  di: Mohamed S. Dabour, et al.
  Pubblicazione: (2026)